Citations

Mayo Clinic

Showing 10 of 108572 citations.

Cardiorespiratory fitness and morbidity and mortality in patients with non-small cell lung cancer: a prospective study with propensity score weighting
Dun, Yaoshan , Cui, Ni, Wu, Shaoping , Fu, Siqian, Ripley-Gonzalez, Jeffrey W. , Zhou, Nanjiang , Zeng, Tanghao, Li, Dezhao, Lau, Wan Yee , Du, Yang , Squires, Ray W. , Olson, Thomas P. , Liu, Suixin , Dun, Yaoshan , Chen, Mi , Ren, Yu , Thomas, Randal J. , Liu, Suixin

Annals of Medicine | December 21, 2023 | Volume: 55 | Issue: 2 | Pages: No page available

10.1080/07853890.2023.2295981 | PMID 38128485 Get It

Vitamin and Mineral Supplementation, Weight Gain, and Poor Appetite in Patients With Cancer: Many Questions and Fewer Answers
Haemmerle, Robert , Jatoi, Aminah , Haemmerle, Robert J

JCO Oncology Practice | December 21, 2023 | Volume: 20 | Issue: 3 | Pages: 323-327

10.1200/op.23.00480 | PMID 38127854 Get It

Patients with cancer or with a history of cancer often seek nutritional advice. In turn, cancer health care providers are often asked questions related to nutrition and cancer. Should I take high-dose vitamins or other high-dose supplements? Should I take a regular-dose vitamin or other regular-dose nutritional supplements? Will I experience weight loss during postoperative chemotherapy? What should be my weight goals during and after adjuvant therapy? In the setting of advanced cancer, what should I do to keep my appetite and weight up? This review attempts to provide data-driven answers to some of these commonly posed questions.
Anatomic Approach to Common and Uncommon Manifestations of Thoracic Leukemias with Radiologic-Pathologic Correlation
Koo, Chi Wan , Lima, Livia Maria Frota, Kerper, Allison , Lo, Ying‐Chun , Frota Lima, Livia Maria, Lo, Ying-Chun , Kerper, Allison L.

Radiology: Cardiothoracic Imaging | December 21, 2023 | Volume: 5 | Issue: 6 | Pages: No page available

10.1148/ryct.230151 | PMID 38166347 Get It

Supercharging collaboration for bipolar research—Breakthrough discoveries for thriving with bipolar disorder (BD2)
Altimus, Cara M. , Baxi, Emily G. , Frye, Mark A. , Nestler, Eric J. , Pham, Dániel , Burdick, Katherine E. , Burdick, K E

Bipolar Disorders | December 21, 2023 | Volume: 25 | Issue: 8 | Pages: 619-623

10.1111/bdi.13398 | PMID 38127002 Get It

The New Year for JAAOS
Rose, Peter S.

Journal of the American Academy of Orthopaedic Surgeons | December 21, 2023 | Volume: 32 | Issue: 1 | Pages: 1-1

10.5435/jaaos-d-23-01039 | PMID 38127640 Get It

NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
Rimel, B.J. , Enserro, Danielle , Bender, David , Jackson, Camille Gunderson, Tan, Annie , Alluri, Nitya , Borowsky, Mark E., Moroney, John W. , Hendrickson, Andrea Wahner, Backes, Floor , Swisher, Elizabeth M. , Powell, Matthew A. , Mackay, Helen , Rimel, Bobbie J , Swisher, Elizabeth M , Backes, Floor

Cancer | December 21, 2023 | Volume: 130 | Issue: 8 | Pages: 1234-1245

10.1002/cncr.35151 | PMID 38127487 Get It

AbstractPurposeThis paper reports the efficacy of the poly (ADP‐ribose) polymerase inhibitor olaparib alone and in combination with the antiangiogenesis agent cediranib compared with cediranib alone in patients with advanced endometrial cancer.MethodsThis was open‐label, randomized, phase 2 trial (NCT03660826). Eligible patients had recurrent endometrial cancer, received at least one (<3) prior lines of chemotherapy, and were Eastern Cooperative Oncology Group performance status 0 to 2. Patients were randomly assigned (1:1:1), stratified by histology (serous vs. other) to receive cediranib alone (reference arm), olaparib, or olaparib and cediranib for 28‐day cycles until progression or unacceptable toxicity. The primary end point was progression‐free survival in the intention‐to‐treat population. Homologous repair deficiency was explored using the BROCA‐GO sequencing panel.ResultsA total of 120 patients were enrolled and all were included in the intention‐to‐treat analysis. Median age was 66 (range, 41–86) years and 47 (39.2%) had serous histology. Median progression‐free survival for cediranib was 3.8 months compared with 2.0 months for olaparib (hazard ratio, 1.45 [95% CI, 0.91‐2.3] p = .935) and 5.5 months for olaparib/cediranib (hazard ratio, 0.7 [95% CI, 0.43–1.14] p = .064). Four patients receiving the combination had a durable response lasting more than 20 months. The most common grade 3/4 toxicities were hypertension in the cediranib (36%) and olaparib/cediranib (33%) arms, fatigue (20.5% olaparib/cediranib), and diarrhea (17.9% cediranib). The BROCA‐GO panel results were not associated with response.ConclusionThe combination of cediranib and olaparib demonstrated modest clinical efficacy; however, the primary end point of the study was not met. The combination was safe without unexpected toxicity.
Comparison of da Vinci Single Port vs Si Systems for Transoral Robotic-Assisted Surgery
Oberhelman, Nicholas J., Bruening, Jennifer , Abel, Kathryn M. Van , Sumer, Baran D. , Andersen, Peter E. , Li, Ryan J. , Van Abel, Kathryn M , Jackson, Ryan S. , Holsinger, F. Christopher , Chan, Jason Y. K. , Gross, Neil D , Clayburgh, Daniel

JAMA Otolaryngology–Head & Neck Surgery | December 21, 2023 | Volume: 150 | Issue: 2 | Pages: 165

10.1001/jamaoto.2023.3994 | PMID 38127360 Get It

Importance Transoral robot-assisted surgery (TORS) continues to have a major role in the treatment of oropharyngeal cancer. As new iterations of robotic technology are increasingly utilized, it is important to share learning experiences and clinical outcomes data, to optimize technical efficiency and clinical care. Observations This was a retrospective review of a large academic institution’s initial clinical use of the da Vinci Single Port (SP) compared with the da Vinci Si (Si) system. A total of 205 TORS cases were reviewed: 109 in the SP group (November 22, 2018, through September 30, 2020), and 96 in the Si group (January 1, 2016, through November 12, 2018). Both groups had comparable operative times, rates of postoperative pharyngeal hemorrhage, length of hospital stay, and duration of nasogastric feeding tube use. There was no difference in pathological characteristics, rates of positive margins, or indications for or time to initiation of adjuvant therapy between the groups. The collective experience of 6 faculty members—who have trained 139 TORS surgeons for the SP system rollout—was compiled to provide a summary of learning experiences and technical notes on safe and efficient operation of the SP system. Conclusions and Relevance This Review found that the functional and oncologic outcomes were comparable between TORS cases performed with the Si and SP systems, and they had similar complication rates. Recognized advantages of the SP over the Si system include the availability of bipolar-energized instruments, a usable third surgical arm, and improved camera image quality.
Author Response: Identifying metabolic features of colorectal cancer liability using Mendelian randomization
Tan, Vanessa Y. , Huyghe, Jeroen R. , Li, Li , Pai, Rish K. , Figueiredo, Jane C. , Bull, Caroline J. , Hazelwood, Emma , Bell, Joshua A. , Constantinescu, Andrei‐Emil , Borges, Maria Carolina , Legge, Danny , Burrows, Kimberley , Brenner, Hermann , Castellvı́-Bel, Sergi , Chan, Andrew T. , Kweon, Sun-Seog , Marchand, Loı̈c Le , Cheng, Iona C. , Murphy, Neil , Gunter, Marc J. , Timpson, Nicholas J. , Vincent, Emma E.

No container title available | December 21, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.87894.3.sa2 Get It

Identifying metabolic features of colorectal cancer liability using Mendelian randomization
Bull, Caroline J. , Hazelwood, Emma , Tan, Vanessa Y. , Legge, Danny , Huyghe, Jeroen R. , Li, Li , Pai, Rish K. , Figueiredo, Jane C. , Bull, Caroline J , Legge, Danny , Hazelwood, Emma , Bell, Joshua A. , Constantinescu, Andrei‐Emil , Borges, Maria Carolina , Burrows, Kimberley , Brenner, Hermann , Castellvı́-Bel, Sergi , Chan, Andrew T. , Kweon, Sun-Seog , Marchand, Loı̈c Le , Cheng, Iona C. , Murphy, Neil , Gunter, Marc J. , Timpson, Nicholas J. , Vincent, Emma E.

eLife | December 21, 2023 | Volume: 12 | Issue: No issue available | Pages: No page available

10.7554/elife.87894.3 Get It

Background: Recognizing the early signs of cancer risk is vital for informing prevention, early detection, and survival. Methods: To investigate whether changes in circulating metabolites characterize the early stages of colorectal cancer (CRC) development, we examined the associations between a genetic risk score (GRS) associated with CRC liability (72 single-nucleotide polymorphisms) and 231 circulating metabolites measured by nuclear magnetic resonance spectroscopy in the Avon Longitudinal Study of Parents and Children (N = 6221). Linear regression models were applied to examine the associations between genetic liability to CRC and circulating metabolites measured in the same individuals at age 8 y, 16 y, 18 y, and 25 y. Results: The GRS for CRC was associated with up to 28% of the circulating metabolites at FDR-P < 0.05 across all time points, particularly with higher fatty acids and very-low- and low-density lipoprotein subclass lipids. Two-sample reverse Mendelian randomization (MR) analyses investigating CRC liability (52,775 cases, 45,940 controls) and metabolites measured in a random subset of UK Biobank participants (N = 118,466, median age 58 y) revealed broadly consistent effect estimates with the GRS analysis. In conventional (forward) MR analyses, genetically predicted polyunsaturated fatty acid concentrations were most strongly associated with higher CRC risk. Conclusions: These analyses suggest that higher genetic liability to CRC can cause early alterations in systemic metabolism and suggest that fatty acids may play an important role in CRC development. Funding: This work was supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol, the Wellcome Trust, the Medical Research Council, Diabetes UK, the University of Bristol NIHR Biomedical Research Centre, and Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work used the computational facilities of the Advanced Computing Research Centre, University of Bristol - http://www.bristol.ac.uk/acrc/ .
Identification of Clinical Drivers of Left Atrial Enlargement Through Genomics of Left Atrial Size
Agrawal, Vineet , Manouchehri, Ali , Shi, Mingjian , Bagheri, Minoo , Gupta, Deepak K. , Kullo, Iftikhar J. , Luo, Yuan , McNally, Elizabeth M. , Puckelwartz, Megan J. , Wells, Quinn S. , Shi, Mingjian , Bagheri, Minoo , Gupta, Deepak K , Kullo, Iftikhar J , Luo, Yuan , McNally, Elizabeth M , Puckelwartz, Megan J , Ferguson, Jane F , Wells, Quinn S , Mosley, Jonathan D , Vaitinadin, Nataraja Sarma , Ferguson, Jane F.

Circulation: Heart Failure | December 21, 2023 | Volume: 17 | Issue: 1 | Pages: No page available

10.1161/circheartfailure.123.010557 | PMID 38126226 Get It

BACKGROUND: Greater left atrial size is associated with a higher incidence of cardiovascular disease and mortality, but the full spectrum of diagnoses associated with left atrial enlargement in sex-stratified clinical populations is not well known. Our study sought to identify genetic risk mechanisms affecting left atrial diameter (LAD) in a clinical cohort. METHODS: Using Vanderbilt deidentified electronic health record, we studied 6163 females and 5993 males of European ancestry who had at least 1 LAD measure and available genotyping. A sex-stratified polygenic score was constructed for LAD variation and tested for association against 1680 International Classification of Diseases code–based phenotypes. Two-sample univariable and multivariable Mendelian randomization approaches were used to assess etiologic relationships between candidate associations and LAD. RESULTS: A phenome-wide association study identified 25 International Classification of Diseases code–based diagnoses in females and 11 in males associated with a polygenic score of LAD (false discovery rate q<0.01), 5 of which were further evaluated by Mendelian randomization (waist circumference [WC], atrial fibrillation, heart failure, systolic blood pressure, and coronary artery disease). Sex-stratified differences in the genetic associations between risk factors and a polygenic score for LAD were observed (WC for females; heart failure, systolic blood pressure, atrial fibrillation, and WC for males). By multivariable Mendelian randomization, higher WC remained significantly associated with larger LAD in females, whereas coronary artery disease, WC, and atrial fibrillation remained significantly associated with larger LAD in males. CONCLUSIONS: In a clinical population, we identified, by genomic approaches, potential etiologic risk factors for larger LAD. Further studies are needed to confirm the extent to which these risk factors may be modified to prevent or reverse adverse left atrial remodeling and the extent to which sex modifies these risk factors.